QNTM -
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 6.2 -0.28 (-4.49%) |
--- |
--- |
0.14 (2.45%) |
--- |
-0.28 (-4.49%) |
--- |
--- |
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 94.22
- VWAP:
- 5.92
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
Dec 23, 2025 13:00
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Dec 19, 2025 21:52
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
Nov 25, 2025 21:00
Quantum BioPharma Ltd. Provides Corporate Update
Oct 31, 2025 23:51
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
Oct 20, 2025 12:30
Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case
Oct 03, 2025 11:00
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
Jun 13, 2025 11:00
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
Apr 24, 2025 11:00
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
Apr 03, 2025 11:00
Quantum BioPharma Shares Are Up Over 80%: What's Going On?
Feb 06, 2025 20:22